Skip Navigation

European Heart Journal 1999 20(11):808-812; doi:10.1053/euhj.1998.1454
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kontny, F.
Right arrow Articles by Abildgaard, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kontny, F.
Right arrow Articles by Abildgaard, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Fibrin monomer antigen; a novel marker of mortality in acute myocardial infarction

F. Kontnya,b,f1, C.E. Dempflec and U. Abildgaardd,b

a Department of Cardiology, Aker University Hospital, Oslo, Norway
d Department of Haematology, Aker University Hospital, Oslo, Norway
b Aker University Hospital, Oslo, Norway
c Division of Haematology, University Clinic, Mannheim, Germany

revised November 10, 1998; accepted November 12, 1998

Abstract

Aims A novel sensitive method for analyses of soluble fibrin monomer antigen was used to assess the predictive value of fibrin monomer when estimating mortality after acute myocardial infarction.

Methods and Results Fibrin monomer was measured in plasma samples from 293 patients enrolled in a randomized clinical trial of low molecular weight heparin (dalteparin) in acute myocardial infarction (the FRAMI trial). Samples taken on days 2 and 7 were analysed using the Enzymun-Test FM®(Boehringer Mannheim, Germany). Non-survivors had significantly higher fibrin monomer levels relative to survivors (day 2, median (min–max): 1·8mg.l–1(<0·01–73·1) vs 0·4mg.l–1(<0·01–103·5),P<0·0001). Fibrin monomer levels were significantly associated with congestive heart failure (P<0·001), enzymatic infarct size (P<0·0001), dalteparin treatment (P<0·001), and thrombolytic therapy (P=0·016). The relationship between fibrin monomer and mortality remained statistically significant after adjustment for these variables. In logistic regression analyses, fibrin monomer levels, age and congestive heart failure were all independent predictors of fatal outcome.

Conclusions Increased fibrin monomer level is an independent predictor of mortality in patients with myocardial infarction. It allows further risk stratification when combined with known risk factors such as age and presence of congestive heart failure.

Key Words: Acute myocardial infarction • mortality • thrombin activity • fibrin monomer • coagulation activity

f1 Correspondence: Frederic Kontny MD, Division of Cardiology, Aker University Hospital, N-0514 Oslo, Norway.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al.
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad
Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.